- 分析性表徵 -
The Analytical Characterisation of Biotherapeutics at PEGS Europe brings analytical scientists together to share their knowledge and experiences in developing new approaches to characterize molecules and residual impurities; while expanding their toolbox to include exciting technologies such as ARMES, aptamers, native MS and MAM, etc.

Final Agenda

11月20日(三)

07:45 Registration and Morning Coffee

STANDARDS AND REGULATORY CONSIDERATIONS FOR ADVANCED THERAPEUTICS AND BIOSIMILARS

08:30 Chairperson’s Opening Remarks

Jonathan Bones, PhD, Principal Investigator, CCL, National Institute for Bioprocessing Research and Training


08:35 KEYNOTE PRESENTATION: An International Collaboration: Towards the Standardisation of Gene Therapy

Yuan Zhao, PhD, Principal Scientist, Leader, Gene Therapy Section, Advanced Therapy Division, NIBSC, Medicines & Healthcare Products
	Regulatory AgencyYuan Zhao, PhD, Principal Scientist, Leader, Gene Therapy Section, Advanced Therapy Division, NIBSC, Medicines & Healthcare Products Regulatory Agency

Potential safety risks, limited efficacy, or ethical conflicts may present challenges in the success of developing GTMP. Manufacturing hurdles, including changes in production sites and manufacturing processes, pose challenges to developers regarding reproducibility and comparability of results for gene therapy. Introduction of an International Standard for gene therapy is especially important, given the usually orphan nature of the diseases to be treated with gene therapy, hampering the comparison of cross-trial and cross-manufacturing results. This presentation will discuss challenges and regulatory perspectives in quality control and standardization of gene therapy and an international effort in developing the 1st WHO International Standard for gene therapy products.

09:05 USP Standards and Best Practices for Advanced Therapies

Atouf_FouadFouad Atouf, PhD, Vice President, Global Biologics, U.S. Pharmacopeia

The development of advanced therapy medicinal products offers great opportunities for therapeutic innovation; some challenges remain to be resolved for successful development and entry of these products to the healthcare market. Some of the challenges relate to the lack of consistency in quality of raw materials and the lack of harmonized analytical methods across the industry. The United States Pharmacopeia (USP) is committed to working with regulators and developers of advanced therapies on the standardization of analytical methods to assess the quality of these products throughout their lifecycle. This presentation will provide an overview of best practices and standardized procedures and associated physical reference materials in support of this important segment of the industry.

09:35 Mapping Analytical Methods for Quality Assessment of Biotherapeutics and Biosimilars; Quality Attributes and Regulatory Considerations Perspectives

Hegazy_MahaMaha Hegazy, PhD, Professor, Analytical Chemistry, Cairo University

The FDA, EMA, and ICH have drawn attention to a number of structural features that have to be assessed to confirm consistent batch production and ensuring control of the manufacturing process for regulatory acceptance. Significant differences between batches need to be investigated, thus integrated advanced analytical methods with new tools of design of experiments (DOE) and data analysis are needed to generate maximum information for quality assessment of biotherapeutics and comparability of biosimilars to the reference product. Mapping analytical methods for multiple quality attributes is also required to ensure the method’s ability to detect relevant differences between samples.

10:05 Bispecific Binding Kinetics Analysed with a Two-Colour switchSENSE® Biosensor

Rant_Ulrich_RBEUlrich Rant, PhD, CEO, Dynamic Biosensors GmbH


10:35 Coffee Break in the Exhibit Hall with Poster Viewing

NEW TOOLS AND APPROACHES

11:15 Anisotropy Resolved Multi-Dimensional Emission Spectroscopy (ARMES): A Multivariate Approach to Intrinsic Protein Emission Analysis

Ryder_AlanAlan G. Ryder, PhD, Professor, Nanoscale Biophotonics Laboratory, National University of Ireland Galway

Fluorescence anisotropy can be related to protein structure, size, and aggregation profile. When implemented using multi-dimensional measurements of intrinsic protein emission and combined with multivariate analysis, one can extract potentially very useful diagnostic information. Here we show how these 4D measurements can be applied to the study of protein structure changes, PEGylation reactions, and for bioreactor monitoring.

11:45 Aptamers and Enzyme Cascades as New Tools for Analytical Characterization of Biopharmaceuticals

Lohrig_Urs_PPCUrs Lohrig, PhD, Lab Head, Physico-Chemical Characterisation, Novartis

Probing higher order structure of biopharmaceuticals is the domain of instrumental analytics like CD, FT-IR, NMR and X-ray crystallography. Here, we present two simple approaches to supplement the analytical toolbox: Aptamer technology and an Analytical Cascade of Enzymes (ACE) – both probing molecular structures. Aptamers offer an adoptable, not immunogenic-driven selection process and long-term supply of critical reagent in contrast to polyclonal antibodies. ACE detects structural differences in mAbs at a 1% level – a range inaccessible by most instrumental methods.

12:15 Potent Bispecifics, Overcoming Analytical Challenges Enroute Preparation for FIH

Dubey_SachinSachin Dubey, PhD, Deputy Director/Head, Formulation, Analytical and Drug Production Development, Glenmark Pharmaceuticals SA

There are around 130 ongoing clinical trials with different bispecifics formats (including Glenmark’s proprietary BEAT molecules); they are potent and are dosed at extremely low levels (low ng/mL concentration). Preparing for FIH at such low concentration is a significant challenge from the analytical standpoint – quantification is challenging, release testing has to be adapted, and prevention against surface adsorption has to be ensured. Product characterization, de-risking manufacturing, and in-use stability for IV infusion are required to be carefully designed and executed with additional controls. Glenmark has three bispecifics in clinical development and experiences gained during their development will be discussed.

12:45 Presentation to be Announced



13:15 Luncheon Presentation I to be Announced

13:45 Luncheon Presentation II to be Announced

14:15 Session Break

HCP QUANTITATION

14:30 Chairperson’s Remarks

Fouad Atouf, PhD, Vice President, Global Biologics, U.S. Pharmacopeia

14:35 Quantitation of HCP by Mass Spectrometry as a Method to Control the Quality of Biopharmaceuticals

Gervais_AnnickAnnick Gervais, PhD, Director, Analytical Development, Biologicals, UCB Pharma SA


15:05 Monitoring of Clearance of Lipase Host Cell Proteins in mAb Manufacturing Using a LC-MRM Quantitation Method

Chen_RachelRachel Chen, PhD, Scientist II, Analytical Development, Biogen

Successful removal of host cell proteins (HCPs) is very important for biopharmaceutical product development to ensure product quality and safety. Recently, it has been demonstrated that certain lipases may be the cause for enzymatic degradation of polysorbate 20 and 80, which are common surfactants used in protein formulations. An LC-MS/MS method was developed to achieve sub ppm quantitation level of three lipases. The method has been applied to monitor the clearance of lipases for various mAbs under different downstream processes.

15:35 Refreshment Break in the Exhibit Hall with Poster Viewing

NATIVE MS AND MAM

16:15 The Transition to Native MS in a Biopharmaceutical Development Lab – Lessons Learned and the Road Ahead

Kristensen_DanBachDan Bach Kristensen, PhD, Principal Scientist, Symphogen

In recent years, native MS has gained significant popularity as a tool for intact mass analysis of large biomolecules. Key strengths include the ability to interface a variety of chromatographic techniques with the MS, and the excellent quality of the spectral data. At Symphogen, native MS is established as the method of choice for intact mass analysis, and here learnings from the transition to native MS and thoughts on future applications will be presented.

16:45 Probing Biopharmaceutical Microheterogeneity Using Native LC-MS

Bones_JonathanJonathan Bones, PhD, Principal Investigator, CCL, National Institute for Bioprocessing Research and Training

Hyphenation of charge variant analysis using pH gradient cation-exchange chromatography to high-resolution Orbitrap mass spectrometry under native conditions (CVA-MS) has recently been described. Here we demonstrate the power of CVA-MS for profiling microheterogeneity of biopharmaceutical product quality attributes on both drug substance and drug product. We will also discuss how high-resolution native LC-MS can be applied for automated process monitoring when combined with automation solutions to create a data generation engine to support Manufacturing 4.0.

17:15 A Reliable and Automated Workflow for LC-MS MAM Analysis of Biopharmaceuticals – From High Throughput Sample Preparation to Data Evaluation

Patrick Sascha Merkle, PhD, Postdoc, Analytical Development & Characterization, Novartis Pharma AG

The LC-MS multi-attribute method (MAM) has emerged as a promising approach for the characterization and relative quantification of critical quality attributes on biopharmaceutical molecules. Here, we present our peptide-level LC-MS MAM workflow that relies on high-throughput sample preparation, high-resolution MS acquisition, and automated data evaluation in the Genedata Refiner MS software. We envisage that the simplicity and state of automation of the presented LC-MS MAM workflow may allow its routine use in a non-expert laboratory.

17:45 Networking Reception in the Exhibit Hall with Poster Viewing

18:45 Problem-Solving Breakout Discussions*

Topic: Native MS in Biopharmaceutical Development

Moderator: Dan Bach Kristensen, PhD, Principal Scientist, Symphogen

  • How is native MS applied during biopharmaceutical development?
  • What are the advantages/disadvantages relative to conventional intact MS?
  • How robust is the native MS platform?
  • What kind of non-covalent interactions are people studying with native MS?
  • Is native MS currently applied in QC (release testing according to specifications)?

Topic: MAM – A Moving Target

Moderator: Matthias Berg, PhD, Group Head, Analytical Development and Characterisation (ADC) – Mass Spectrometry, Novartis Pharma AG

  • Peptide mapping versus subunit analysis
  • Define the limits of relevance
  • High resolution versus low resolution MS instrumentation for MAM

Topic: In-use Stability for Biologics

Moderator: Sachin Dubey, PhD, Deputy Director/Head, Formulation, Analytical and Drug Product Development, Glenmark Pharmaceuticals

  • Generally acceptable approaches and good practices
  • What need to be tested and what shall be the quality requirements for the tests
  • Gearing up for upcoming USP<800>

 

 

 

19:45 End of Day

11月21日(四)

08:00 Registration and Morning Coffee

CHARACTERIZING COMPLEX MODALITIES

08:30 Chairperson’s Remarks

Annick Gervais, PhD, Director, Analytical Development, Biologicals, UCB Pharma SA

08:35 Analytical Characterization of a Complex Product: Lentiviral Vector

Deuel_JuliaJulia Deuel, MSc, Senior Scientist, Analytical Characterization, bluebird Bio

Traditional molecular biology techniques can provide in-depth understanding of lentiviral vector activity and structure, but are often low-throughput and highly variable, contributing disproportionately to COGs, delays in batch release, and potential batch failures if assays cannot be repeated. Presented here are techniques for characterization of lentiviral vectors with a focus on elucidation of vector structure for evaluation of lot consistency and lentiviral vector comparability following manufacturing changes. These include modifications to commonly used techniques along with new technologies to provide a broad evaluation of lentiviral vector characteristics and impurities.

09:05 Strategy to Establish Clinically Relevant Specifications at Launch

Stults_JohnJohn Stults, PhD, Director, Protein Analytical Chemistry, Genentech, Inc.

Specification acceptance criteria are typically based on the understanding of critical quality attributes, clinical experience, and manufacturing capability. With shortened development timelines and few clinical lots, justifications of acceptance criteria are focused on science- and risk-based assessments of patient impact, providing a balance between appropriate control over high-risk attributes to ensure product quality for the patient, and flexibility for low-risk attributes, as appropriate, for a robust supply chain.

09:35 Characterization from Developability to BLA

Menet_Jean-MichelJean-Michel Menet, PhD, Head, Characterization, Biologics Development/BioAnalytics, Sanofi

Characterization toolbox is evolving along the development phase of therapeutic proteins (i.e., from developability studies to the filing of the BLA) and to suit protein modality (e.g., IgG1 to multispecific). Examples applied to monospecific and multispecific antibodies will be given showing toolbox used for early phase projects and for late phase projects. Approaches under development for CQA-driven CMC development will also be presented: high order structure technologies such as HDX-MS and NMR, native MS, MAM.

10:05 A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules

Jana Hersch, Scientific Consultant, Biologics, Genedata

We present a workflow system that enables systematic developability and manufacturability assessments, using both in silico and high throughput analytical confirmatory methods, over the entire biologics R&D process from initial discovery all the way to final candidate selection. We show use cases for mAbs and other complex multi/bispecific formats and discuss building predictive developability models utilizing this system. We also present the underlying molecule and task management needed for analytical organizations to accomplish this.

10:35 Coffee Break in the Exhibit Hall with Poster Viewing

11:15 Kinetic Mechanism of Controlled Fab-Arm Exchange for the Formation of Bispecific Immunoglobulin G1 Antibodies

Mark Chiu, PhD, Associate Director, BioTherapeutics Analytical Development, Janssen Research & Development, LLC

A combination of FRET, non-reducing SDS-PAGE, and strategic mutation of the Ab hinge region was employed to characterize the cFAE process. Fluorescence correlation spectroscopy (FCS) was used to determine the affinity of parental (homodimer) and bispecific (heterodimer) interactions within the CH3 domain to further clarify the thermodynamic basis for bsAb formation. The result is a rate constant mechanism with the dissociation of the K409R parental Ab into half-Ab controlling the overall rate of the reaction.

11:45 Rapid Release of Autologous Cell Therapy Products to Patients: A Road Less Travelled

Sra_KuldipKuldip Sra, PhD, Senior Director, Technical Operations, CRISPR Therapeutics

For autologous cell therapy products, each patient is a product batch. Manufacturing is a very tedious and manual process. Urgency to release the product quickly to the patient is very high. The presentation will cover the implementation of rapid analytical methods to release the final product in a desired timeframe to patients.

Wyatt Technology 12:15 Luncheon Presentation I to be Announced

 

12:45 Luncheon Presentation II (Opportunity Available)

13:15 Dessert Break in the Exhibit Hall with Poster Viewing

14:00 End of Analytical Characterisation of Biotherapeutics

17:00 Dinner Short Course Registration*

17:3020:30 Dinner Short Courses


Recommended Short Course*

SC8: Advanced Analytical Technologies for Developability and Early Formulation Assessments - LEARN MORE

*Separate registration required.

* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English





免費電子郵件通知服務